A randomized, double-blind, placebo controlled, parallel group, Phase II multi-centric trial to assess safety, tolerability and efficacy of PHD-2 Inhibitor, ZYAN1 in the treatment of anemia in pre-dialysis chronic kidney disease patients.

Trial Profile

A randomized, double-blind, placebo controlled, parallel group, Phase II multi-centric trial to assess safety, tolerability and efficacy of PHD-2 Inhibitor, ZYAN1 in the treatment of anemia in pre-dialysis chronic kidney disease patients.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 31 May 2017

At a glance

  • Drugs ZYAN 1 (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Sponsors Cadila Healthcare
  • Most Recent Events

    • 31 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top